Egrifta and Multivitamin drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Egrifta (tesamorelin acetate) and Multivitamin (ascorbic acid; biotin; cyanocobalamin; dexpanthenol; ergocalciferol; folic acid; niacinamide; pyridoxine hydrochloride; riboflavin phosphate sodium; thiamine hydrochloride; vitamin a; vitamin e). Common drug interactions include injection site erythema among females and hypoaesthesia among males.

The phase IV clinical study analyzes what interactions people have when they take Egrifta and Multivitamin. It is created by eHealthMe based on reports of 49 people who take the same drugs from the FDA, and is updated regularly.

What is Egrifta?

Egrifta has active ingredients of tesamorelin acetate. eHealthMe is studying from 3,443 Egrifta users. Check the latest studies of Egrifta.

What is Multivitamin?

Multivitamin has active ingredients of ascorbic acid; biotin; cyanocobalamin; dexpanthenol; ergocalciferol; folic acid; niacinamide; pyridoxine hydrochloride; riboflavin phosphate sodium; thiamine hydrochloride; vitamin a; vitamin e. It is often used in vitamin supplementation. eHealthMe is studying from 83,597 Multivitamin users. Check the latest studies of Multivitamin.

On Jul, 31, 2026

49 people who take Egrifta and Multivitamin together, and have interactions are studied.

Egrifta and Multivitamin drug interactions.

What are the common drug interactions of Egrifta and Multivitamin, by gender? *:

female:

Injection site erythema (redness at injection site)
Injection site pruritus (severe itching at injection site)

male:

Hypoaesthesia (reduced sense of touch or sensation)
Injection site pain
Haematocrit increased
Haemoglobin increased
Injection site haemorrhage (bleeding from injection site)
Injection site rash
Injection site swelling
Insomnia (sleeplessness)
Prostatic specific antigen increased
Red blood cell count increased

What are the common drug interactions of Egrifta and Multivitamin, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Hypoaesthesia (reduced sense of touch or sensation)
Alanine aminotransferase increased
Aspartate aminotransferase increased
Blood creatinine increased
Epidermal growth factor receptor decreased
Haematocrit increased
Haemoglobin increased
Red blood cell count increased
Skin mass

50-59:

Injection site erythema (redness at injection site)
Injection site haemorrhage (bleeding from injection site)
Injection site pruritus (severe itching at injection site)
Injection site rash
Injection site swelling
Insomnia (sleeplessness)

60+:

Injection site pain
Muscle tightness
Blood glucose increased
Blood triglycerides increased

What are the existing conditions these people have? *

Lipodystrophy Acquired (a regional loss of subcutaneous adipose tissue which usually starts in the face, extends downward acquired): 21 people, 42.86%
Hiv Infection: 15 people, 30.61%
High Blood Pressure: 5 people, 10.20%
Acquired Immunodeficiency Syndrome (disease of the human immune system caused by the human immunodeficiency virus (hiv)): 5 people, 10.20%
Hyperlipidaemia (presence of excess lipids in the blood): 4 people, 8.16%
Depression: 4 people, 8.16%

* Approximation only. Some reports may have incomplete information.

Do you take Egrifta and Multivitamin?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously